Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

Inclusion criteria

• ✓. Part 1 - Healthy trial participants: Understand and voluntarily sign the informed consent form;
• ✓. Part 1 - Healthy trial participants: Age between 18-45 years (inclusive), male or female;
• ✓. Part 1 - Healthy trial participants: Weight between 50-120 kg (inclusive), and BMI between 17.0-28.0 kg/m2 (inclusive);
• ✓. Part 2 - Active non-segmental vitiligo trial participants: 18-65 years old (inclusive), male;
• ✓. Part 2 - Active non-segmental vitiligo trial participants: Diagnosed with non-segmental vitiligo for ≥3 months and \<2 years;
• ✓. Part 2 - Active non-segmental vitiligo trial participants: Total affected BSA 3-50%, and facial affected BSA ≥ 0.5%; T-VASI 3-50 (inclusive), and F-VASI ≥0.5; ≥1 active lesion;
• ✓. Part 2 - : Male participants of reproductive potential agree to use highly effective contraception and avoid sperm donation for 6 months after the last dose.
• ✓. Part 2 - Severe alopecia areata trial participants: 18-60 years old (inclusive), male;

Exclusion criteria